On March 5, 2025 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, "YASKAWA") reported the companies signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot "Maholo" (Press release, Astellas, MAR 5, 2025, View Source [SID1234650923]). In addition, the joint venture will offer platform access to startups and academic institutions, fostering collaboration and innovation in the field of cell therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the pharmaceutical industry, the commercialization of cell therapy faces many challenges stemming from the complex nature of the manufacturing process, in particular, related to the accuracy and reproducibility of cell manufacturing. Furthermore, the need for a skilled workforce, coupled with the time and cost investments required for technology transfer to manufacturing facilities, presents additional hurdles. Based on the memorandum of agreement signed in May, 2024, Astellas and YASKAWA have been advancing discussions toward establishing a joint venture to leverage their mutual strengths and accelerate efforts to address these challenges.
The planned joint venture will leverage Astellas’ expertise in R&D and manufacturing for cell therapy and the dual arm robot "Maholo," developed by YASKAWA’s subsidiary, Robotic Biology Institute. The closing and establishment of the joint venture company are subject to certain closing conditions, including receipt of required regulatory approvals.
Joint Venture Company: Overview
Name
To be determined
Capital
4.5 billion yen (includes capital reserve)
Capital Structure
Astellas 60%, YASKAWA 40%
Establishment
（tentative）
September 2025
Business
Develop a cell therapy product manufacturing platform and
offer access to startups and academic institutions.
1. Explore a manufacturing process with high precision and
reproducibility using ‘Maholo’ and optimize the digitized
manufacturing process with AI
2. Transfer the digitalized manufacturing process to ‘Maholo’
at other manufacturing facilities via one-click* transfer and
develop a cell manufacturing platform that meets GMP conditions
3. Develop manufacturing processes for cell therapy product
candidates of partners, such as academia and startups,
as well as manufacture investigational drugs in GMP facilities
* GMP (Good Manufacturing Practice):
A standard for ensuring the safety and quality of pharmaceuticalproduct manufacturing
* One Click Transfer:
Rapid transfer of established manufacturing process to facilities without hands-on training of workers
Through the establishment of a joint venture and the development of a cell therapy manufacturing platform, Astellas is committed to addressing the challenges of commercializing cell therapy and supporting academia and startup companies in implementing innovative cell therapies. By integrating advanced technologies into its cell therapy expertise, Astellas aims to develop potentially transformative cell therapy for patients with limited or no treatment options. Please visit this for more details.
YASKAWA has provided automation solutions for medical testing processes, including cancer genome diagnostics, iPS cell culture, and PCR testing, through delivering "Maholo." With the establishment of a joint venture, YASKAWA aims to expand the use cases of robots in the field of cell therapy beyond the existing life science field.